C

Can-Fite BioPharma Ltd
D

CANF

1.94000
USD
-0.03
(-1.52%)
Market Closed
Volume
1,076
EPS
-1
Div Yield
-
P/E
-1
Market Cap
11,827,070
OverviewSignalsIdeasNews
Related Instruments
    A
    AEMD
    0.00400
    (1.04%)
    0.39000 USD
    A
    APDN
    -0.01260
    (-7.25%)
    0.16110 USD
    A
    ARAV
    0
    (0%)
    0.000000 USD
    A
    AXON
    -5.56
    (-0.92%)
    599.18 USD
    M
    MESA
    -0.02300
    (-2.63%)
    0.85080 USD
    N
    NVCN
    0
    (0%)
    0.000000 USD
    O
    OCUL
    -0.77000
    (-7.75%)
    9.16000 USD
    More
News

Title: Can/Fite BioPharma Ltd

Sector: Healthcare
Industry: Biotechnology
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed intoa Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).